Hospital
Mcleod Health Clarendon
Mcleod Health Clarendon was paid $10.05M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 20% of everything it billed.
33Billing provider infoMCLEOD HEALTH CLARENDON
MANNING, SC 29102
MANNING, SC 29102
33aNPI1205284411assigned 05/27/2016
33bProvider typeRural Acute Care Hospital
28Total paid$10.05M
24GClaims400,465
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in South Carolina
Rank by total paid#1 of 5
Median peer was paid$6.15M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ERVIN, SAMUEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 58,051 | $1.87M | |
| 2019 | 60,932 | $1.31M | |
| 2020 | 51,830 | $944K | |
| 2021 | 61,977 | $1.24M | |
| 2022 | 64,038 | $1.37M | |
| 2023 | 55,511 | $1.72M | |
| 2024incomplete | 48,126 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 20% | 26,398 | 20,760 | $1.97M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 14% | 15,080 | 4,246 | $1.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.7% | 21,466 | 19,959 | $778K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.8% | 4,075 | 3,814 | $581K |
| 87430 | 5.4% | 2,742 | 2,617 | $544K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.1% | 4,788 | 4,509 | $517K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 4,674 | 4,440 | $340K |
| 81001 | 2.9% | 13,166 | 11,901 | $287K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.8% | 4,075 | 3,908 | $285K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.7% | 2,672 | 2,498 | $272K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.4% | 7,044 | 5,877 | $240K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 2,353 | 2,181 | $157K |
171 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 7,762 | $151K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.4% | 1,670 | $145K |
| 99284 | Emergency room visit (serious) | 1.4% | 17,140 | $143K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 2,779 | $131K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,348 | $127K |
| 81025 | 1.2% | 7,021 | $124K | |
| 81003 | 1.2% | 4,314 | $122K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 8,818 | $120K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 4,296 | $109K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,240 | $85K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,069 | $82K |
| 73630 | <1% | 1,355 | $80K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 801 | $74K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,676 | $68K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 962 | $67K |
| 73610 | <1% | 948 | $67K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,607 | $67K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,180 | $55K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,625 | $52K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,685 | $50K |
| 73030 | <1% | 1,063 | $50K | |
| 73564 | <1% | 814 | $48K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,378 | $43K |
| 73130 | <1% | 526 | $40K | |
| 36416 | <1% | 1,950 | $38K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,806 | $38K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,180 | $35K |
| 99285 | Emergency room visit (most serious) | <1% | 9,306 | $34K |
| 74018 | <1% | 645 | $28K | |
| 59025 | Fetal non-stress test | <1% | 784 | $23K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,457 | $19K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,561 | $17K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,917 | $16K |
| 80305 | <1% | 602 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,057 | $15K |
| 72100 | <1% | 349 | $14K | |
| 73502 | <1% | 376 | $13K | |
| 85027 | <1% | 2,563 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 363 | $13K |
| 80053 | Comprehensive metabolic panel | <1% | 15,998 | $13K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,249 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,544 | $12K |
| 93356 | <1% | 27 | $11K | |
| 87077 | <1% | 506 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 963 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,684 | $8K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 73 | $8K |
| 73110 | <1% | 126 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 263 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,324 | $7K |
| 96376 | <1% | 1,799 | $7K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 314 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 43 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 82 | $6K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 151 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 98 | $6K |
| 93971 | <1% | 45 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,190 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $5K |
| 72110 | <1% | 92 | $4K | |
| 87490 | <1% | 59 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 886 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 105 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 1,584 | $4K |
| 77080 | <1% | 45 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 43 | $3K |
| 87807 | <1% | 620 | $3K | |
| 85610 | <1% | 5,383 | $3K | |
| 71250 | <1% | 26 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,329 | $2K |
| 72050 | <1% | 25 | $2K | |
| 72040 | <1% | 41 | $2K | |
| 97161 | <1% | 379 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 430 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 38 | $2K |
| 73140 | <1% | 13 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,191 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 405 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $2K |
| 73590 | <1% | 24 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $2K |
| 74021 | <1% | 46 | $2K | |
| 73562 | <1% | 30 | $1K | |
| 86850 | <1% | 297 | $1K | |
| 76801 | <1% | 20 | $1K | |
| 97164 | <1% | 272 | $1K | |
| 86900 | <1% | 732 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,678 | $1K |
| 82948 | <1% | 266 | $944.25 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,983 | $865.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,929 | $768.35 |
| 83735 | <1% | 7,613 | $712.86 | |
| 82803 | <1% | 261 | $636.08 | |
| J3490 | Unclassified drugs | <1% | 1,523 | $433.64 |
| 36600 | <1% | 136 | $426.58 | |
| 82570 | <1% | 42 | $373.23 | |
| 73090 | <1% | 13 | $368.77 | |
| 84484 | <1% | 9,114 | $320.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 634 | $317.69 |
| 82805 | <1% | 16 | $268.48 | |
| 73560 | <1% | 16 | $244.94 | |
| 83690 | <1% | 5,498 | $207.89 | |
| 84439 | <1% | 86 | $195.86 | |
| 83880 | <1% | 3,505 | $187.13 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 991 | $174.91 |
| 87088 | <1% | 471 | $171.56 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,366 | $170.92 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 494 | $138.76 |
| 85007 | <1% | 177 | $114.08 | |
| 80076 | <1% | 1,019 | $111.73 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,398 | $84.60 |
| 97162 | <1% | 12 | $69.91 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 328 | $68.45 |
| 84702 | <1% | 295 | $66.26 | |
| 97167 | <1% | 28 | $65.77 | |
| A9270 | Non-covered item or service | <1% | 1,712 | $50.79 |
| 80061 | Lipid panel | <1% | 618 | $49.69 |
| 87040 | <1% | 3,577 | $37.62 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,680 | $37.59 |
| 90715 | <1% | 69 | $23.93 | |
| 83605 | <1% | 2,828 | $19.50 | |
| 82077 | <1% | 1,041 | $18.38 | |
| 86140 | <1% | 900 | $16.74 | |
| 85730 | <1% | 4,628 | $15.56 | |
| 82247 | <1% | 22 | $15.02 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 306 | $8.52 |
| 85379 | <1% | 1,269 | $8.21 | |
| 80320 | <1% | 557 | $5.00 | |
| 86901 | <1% | 732 | $3.99 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 158 | $1.71 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 436 | $0.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 165 | $0.00 |
| 80179 | 0% | 198 | $0.00 | |
| 87186 | 0% | 1,367 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 108 | $0.00 |
| 80143 | 0% | 242 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 1,511 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 132 | $0.00 |
| 85378 | 0% | 89 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 371 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 25 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 43 | $0.00 |
| 84145 | 0% | 60 | $0.00 | |
| 84156 | 0% | 41 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 13 | $0.00 |
| 84100 | 0% | 60 | $0.00 | |
| 82248 | 0% | 37 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 14 | $0.00 |
| 97168 | 0% | 16 | $0.00 | |
| 94760 | 0% | 70 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 237 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 583 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 451 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 56 | $0.00 |
| 87590 | 0% | 59 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 468 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 258 | $0.00 |
| 85651 | 0% | 120 | $0.00 | |
| 82550 | 0% | 369 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 58 | $0.00 |
| 87205 | 0% | 63 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 250 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 12 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 69 | $0.00 |
| 87140 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 48 | $0.00 |
| 88342 | 0% | 28 | $0.00 | |
| 94644 | 0% | 92 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 40 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 19 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERVIN, SAMUEL (SR VICE PRESIDENT AND CFO)
Parent organizationMCLEOD HEALTH
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.